- Home
- PRME vs CDNA Comparison
PRME vs CDNA Comparison
Compare PRME & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRME
- CDNA
- Stock Information
- Founded
- PRME 2019
- CDNA 1998
- Country
- PRME United States
- CDNA United States
- Employees
- PRME N/A
- CDNA N/A
- Industry
- PRME Medicinal Chemicals and Botanical Products
- CDNA Medical Specialities
- Sector
- PRME Health Care
- CDNA Health Care
- Exchange
- PRME Nasdaq
- CDNA Nasdaq
- Market Cap
- PRME 624.0M
- CDNA 712.2M
- IPO Year
- PRME 2022
- CDNA 2014
- Fundamental
- Price
- PRME $3.72
- CDNA $13.82
- Analyst Decision
- PRME Buy
- CDNA Buy
- Analyst Count
- PRME 6
- CDNA 7
- Target Price
- PRME $8.88
- CDNA $27.67
- AVG Volume (30 Days)
- PRME 3.0M
- CDNA 1.5M
- Earning Date
- PRME 08-07-2025
- CDNA 11-03-2025
- Dividend Yield
- PRME N/A
- CDNA N/A
- EPS Growth
- PRME N/A
- CDNA N/A
- EPS
- PRME N/A
- CDNA 1.00
- Revenue
- PRME $4,961,000.00
- CDNA $340,826,000.00
- Revenue This Year
- PRME $179.58
- CDNA $13.02
- Revenue Next Year
- PRME N/A
- CDNA $12.85
- P/E Ratio
- PRME N/A
- CDNA $13.85
- Revenue Growth
- PRME 739.42
- CDNA 14.72
- 52 Week Low
- PRME $1.11
- CDNA $10.96
- 52 Week High
- PRME $5.17
- CDNA $32.97
- Technical
- Relative Strength Index (RSI)
- PRME 54.32
- CDNA 54.96
- Support Level
- PRME $3.09
- CDNA $12.37
- Resistance Level
- PRME $3.49
- CDNA $14.20
- Average True Range (ATR)
- PRME 0.25
- CDNA 0.73
- MACD
- PRME 0.01
- CDNA 0.27
- Stochastic Oscillator
- PRME 95.49
- CDNA 87.02
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.